Abstract
A phase 1/2 clinical trial evaluating dosing, safety, immunogenicity, and overall survival on metastatic colorectal cancer (mCRC) patients after immunotherapy with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine was performed. We report our extended observations on long-term overall survival and further immune analyses on a subset of treated patients including assessment of cytolytic T cell responses, T regulatory (Treg) to T effector (Teff) cell ratios, flow cytometry on peripheral blood mononuclear cells (PBMCs), and determination of HLA-A2 status. An overall survival of 20 % (median survival 11 months) was observed during long-term follow-up, and no long-term adverse effects were reported. Cytolytic T cell responses increased after immunizations, and cell-mediated immune (CMI) responses were induced whether or not patients were HLA-A2 positive or Ad5 immune. PBMC samples from a small subset of patients were available for follow-up immune analyses. It was observed that the levels of carcinoembryonic antigen (CEA)-specific CMI activity decreased from their peak values during follow-up in five patients analyzed. Preliminary results revealed that activated CD4+ and CD8+ T cells were detected in a post-immunization sample exhibiting high CMI activity. Treg to Teff cell ratios were assessed, and samples from three of five patients exhibited a decrease in Treg to Teff cell ratio during the treatment protocol. Based upon the favorable safety and immunogenicity data obtained, we plan to perform an extensive immunologic and survival analysis on mCRC patients to be enrolled in a randomized/controlled clinical trial that investigates Ad5 [E1-, E2b-]-CEA(6D) as a single agent with booster immunizations.
Similar content being viewed by others
Abbreviations
- Ad5:
-
Adenovirus serotype-5
- Ad5 [E1-]:
-
Adenovirus serotype-5 (Ad5)-based vector platforms with deletions in the early 1 (E1) gene and early 3 (E3) gene regions
- Ad5 [E1-E2b-]:
-
Ad5 [E1-] with additional deletions in the early 2 (E2) gene region
- Ad5 [E1-E2b-]-CEA(6D):
-
Ad5 [E1-, E2b-] containing the CAP1(6D) gene
- AE:
-
Adverse effects
- CAP1:
-
Nine amino acid sequence of CEA
- CAP1(6D):
-
Peptide analog sequence of CAP1
- CEA:
-
Carcinoembryonic antigen
- CMI:
-
Cell-mediated immune
- Con A:
-
Concanavalin A
- CT:
-
Computed tomography
- CTCAE:
-
Common terminology criteria for adverse events
- CTL:
-
Cytotoxic T lymphocytes
- E1:
-
Early 1 gene region
- E2b:
-
Early 2b gene region
- E3:
-
Early 3 gene region
- IFN-γ:
-
Interferon gamma
- mCRC:
-
Metastatic colorectal cancer
- MRI:
-
Magnetic resonance imaging
- NAb:
-
Neutralizing antibody
- NHP:
-
Non-human primates
- PBMCs:
-
Peripheral blood mononuclear cells
- pol:
-
Polymerase gene
- pTP:
-
Pre-terminal protein gene
- RECIST:
-
Response evaluation criteria in solid tumors
- SAEs:
-
Serious adverse effects
- SAFC:
-
Sigma-Aldrich Fine Chemicals
- SFC:
-
Spot-forming cells
- SQ:
-
Subcutaneously
- TAA:
-
Tumor-associated antigens
- Teff:
-
T effector
- Treg:
-
T regulatory
- TNF-α:
-
Tumor necrosis factor alpha
- VP:
-
Viral particles
References
Vergati M, Intrivici C, Huen N-Y, Schlom J, Tsang KY (2010) Strategies for cancer vaccine development. J Biomed Biotechnol. doi:10.1155/2010/596432
Palena C, Schlom J (2010) Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol. doi:10.1155/2010/380697
Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104:599–613
Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10:616–629
Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24:849–862
Campos SK, Barry MA (2007) Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther 7:189–204
Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574–1583
Barouch DH, Kikc SV, Weverling GJ et al (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29:5203–5209
Amalfitano A, Chamberlain JS (1997) Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther 4:258–263
Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS (1998) Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 72:926–933
Hartigan-O’Connor D, Amalfitano A, Chamberlain JS (1999) Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J Virol 73:7835–7841
Seregin SS, Amalfitano A (2009) Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus based vectors. Expert Opin Biol Ther 9:1521–1531
Osada T, Yang XY, Hartman ZC et al (2009) Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 16:673–682
Gabitzsch ES, Xu Y, Balint JP Jr, Hartman ZC, Lyerly HK, Jones FR (2010) Anti-tumor immunity despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunol Immunother 59:1131–1135
Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Gayle RB, Amalfitano A, Jones FR (2009) A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant based vaccine used to induce cell mediated immune responses. Immunol Lett 122:44–51
Gabitzsch ES, Yu X, Yoshida LH, Balint J, Amalfitano A, Jones FR (2009) Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 27:6394–6398
Gabitzsch ES, Xu Y, Balcaitis S, Balint JP Jr, Jones FR (2011) An Ad5 [E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Ther 18:326–335
Gabitzsch ES, Xu Y, Balint JP Jr, Balcaitis S, Sanders-Beer B, Jones FR (2011) Induction and comparison of SIV immunity in Ad5 Naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine. Vaccine 29:8101–8107
Jones FR, Gabitzsch ES, Xu Y et al (2011) Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29:7020–7026
Gabitzsch ES, Jones FR (2011) New recombinant Ad5 vector overcomes Ad5 immunity allowing for multiple safe, homologous immunizations. J Clin Cell Immunol S4:001. doi:10.4172/2155-9899.S4-001
Gabitzsch ES, Balint JP Jr, Xu Y et al (2012) Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform. Vaccine 30:7265–7270
Wieking BG, Vermeer DW, Spanos WC et al (2012) A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther 19:667–674
Morse MM, Chaudhry A, Gabitzsch ES et al (2013) Novel adenoviral vector induces T cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother 62:1293–1301
Thompson JA, Grunert F, Zimmermann W (1991) Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5:344–366
Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9:67–81
Berinstein NL (2002) Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 20:2197–2207
Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337
Gameiro SR, Jammeh ML, Hodge JW (2013) Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. Expert Rev Vaccines 12:617–629
Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J (1997) Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570–4577
Tangri S, Ishioka GY, Huang X et al (2001) Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild type peptide. J Exp Med 194:833–846
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
CTEP Cancer Therapy Evaluation Program (2010) CTCAE and CTC website http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 10 Feb 2012
Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M (2000) Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods 240:143–155
Shafer-Weaver K, Sayers T, Strobl S et al (2003) The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 1:14–23
Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA (2001) Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol 21:287–297
Hobeika AC, Morse MA, Osada T et al (2005) Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 28:63–72
Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Comm 3:207–212
Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048
Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765
Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664
Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094
Higano CS, Schellhammer PF, Small EJ et al (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670–3679
Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804–811
Acknowledgments
The authors wish to thank Susan Thorburn for her assistance in the patient data collection and Ms. Carol Jones for her excellent assistance with grants management. This study was funded by National Cancer Institute Small Business Innovative Research Grant 1R43CA134063, National Cancer Institute Small Business Innovative Research Grant 2R44CA134063, National Cancer Institute Small Business Innovative Research Contract HHSN261200900059C, and National Cancer Institute Small Business Innovative Research Contract HHSN261201100097C.
Conflict of Interest
Joseph P. Balint is a shareholder and employee of Etubics and has stock options in the Company. Elizabeth S. Gabitzsch is a shareholder and employee of Etubics and has stock options in the Company. Adrian Rice is an employee of Etubics and has stock options in the Company. Yvette Latchman is an employee of Etubics and has stock options in the Company. Younong Xu was an employee of Etubics during performance of the study and has stock options in the Company. Gerry L. Messerschmidt is an employee of Etubics and has stock options in the Company. Frank R. Jones is a shareholder and employee of Etubics and has stock options in the Company. Arvind Chaudhry and Michael Morse have no conflicts of interest related to this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Balint, J.P., Gabitzsch, E.S., Rice, A. et al. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunol Immunother 64, 977–987 (2015). https://doi.org/10.1007/s00262-015-1706-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-015-1706-4